Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
An open label, randomized, three-period, three-treatment [Treatment A (test product
administered without water), Treatment B (test product administered with water) and Treatment
C (Reference product administered with water)], six-sequence, crossover, balanced, single
dose oral bioequivalence study.